Objective: ELYPSE is an ongoing multicenter surveillance trial to investigate the efficacy and
tolerability of Lercanidipine (Ler) in daily clinical practice (DCP). Design and Methods …

The efficacy and tolerability of lercanidipine, a new dihydropyridine calcium antagonist, and
of captopril were compared in a randomized, double-blind, multicenter trial in 115 patients …

The safety and tolerability of lacidipine was assessed in a volunteer population, and its
pharmacodynamic and pharmacokinetic profiles evaluated. In nor-motensive subjects …

Background: Lercanidipine, a newly added dihydropyridine, was compared with one of its
older and time tested congener-amlodipine for their efficacy and tolerability. Methods: This …

NORDIL-the Nordic diltiazem intervention study was started in September 1992. This trial is
a prospective randomized open blinded-endpoint (PROBE) multicenter, parallel-group study …

Lacidipine is a new 1, 4-dihydropyridine (DHP) that induces a potent calcium antagonistic
activity on vascular preparations. It has a markedly slow rate of onset, but its effect is still …

In this single-blind crossover study the antihypertensive efficacies of two dihydropyridine
calcium antagonists, sustained-release isradipine and lacidipine, were compared using …

Background: Irrespective of their clinical relevance, side effects cannot be considered a
negligible problem in antihypertensive therapy. The aim of this trial was to evaluate the …

Ambulatory blood pressure monitoring (ABPM) is a particularly useful method for evaluating
the effects of antihypertensive drugs. ABPM allows the therapeutic effect of an agent to be …

Background: Lercanidipine, a novel lipophilic and vasoselective dihydropyridine calcium
antagonist, is an effective antihypertensive drug at dosages of 10 mg once daily in most …